New study highlights the clinical value of UBC® Rapid in detecting invasive bladder cancer

This multicenter study, conducted by Ecke et al. in Germany and published in the Official Journal of the Society of Urologic Oncology, analyzed 732 urine samples. The aim was to compare the diagnostic accuracy of urinary cytology with other urine-based point-of-care tests that are commercially available. This study stands out as the first to compare all available rapid tests on a large group of bladder cancer patients and healthy controls in a single setting.
 
The results of the study indicated that the UBC® Rapid test effectively differentiated between patients with bladder cancer and healthy controls, based on cytokeratin concentrations. These findings further support previous research and demonstrate the high detection rates of bladder cancer cases, particularly for high-grade bladder cancer patients, using the UBC Rapid test.
 
In addition to its diagnostic capabilities, the study highlighted the potential clinical value of the UBC® Rapid test as a urinary biomarker for detecting high-grade non-muscle invasive bladder cancer patients. This discovery could greatly aid in the management of these particular tumors.
 
The link for the article is:
https://www.sciencedirect.com/science/article/abs/pii/S1078143923002259